GNIPST BULLETIN 2015

25-09-2015

25th September, 2015

Volume No.: 49 Issue No.: 02

Vision
TO REACH THE PINNACLE OF GLORY AS A CENTRE OF EXCELLENCE IN THE
FIELD OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES BY KNOWLEDGE
BASED LEARNING AND PRACTICE

Contents

Message from PRINCIPAL

Editorial board
Historical article
News Update
Knowledge based Article
Disease Related Breaking
News
Upcoming Events
Drugs Update
Campus News
Students Section
Editors Note
Archive

GNIPST Photo Gallery

For your comments/contribution

OR For Back-Issues,
mailto:gnipstbulletin@gmail.com
GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY
Website: http://gnipst.ac.in

25-09-2015

MESSAGE FROM PRINCIPAL

"It can happen. It does happen.

But it can't happen if you quit." Lauren Dane.

We are what we repeatedly do.

Excellence then is not an act, but a habit. Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the
last years editors and congratulate the newly selected editors for the current year.
Our first consideration is always in the best interest of the students. Our goal is to promote academic
excellence and continuous improvement.
I believe that excellence in education is aided by creating a learning environment in which all learners are
supported in maximizing their potential and talents. Education needs to focus on personalized learning
and instruction, while promoting an education system that is impartial, universally accessible, and meeting
the needs of all students.
It is of paramount importance that our learners have sufficient motivation and encouragement in order to
achieve their aims. We are all very proud of you, our students, and your accomplishments and look
forward to watching as you put your mark on the profession in the years ahead.
The call of the time is to progress, not merely to move ahead. Our progressive Management is looking
forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in
this direction and fruits of these efforts will be received by our students in the near future. Our Teachers
are committed and dedicated for the development of the institution by imparting their knowledge and play
the role of facilitator as well as role model to our students.
The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive
challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic
needs of our students.
I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the
opportunities and meet the challenges with purpose and determination.
Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on
this path.
My best wishes to all.
Dr. A. Sengupta

Click here to go at the top

1

25-09-2015

EDITORIAL BOARD
CHIEF EDITOR
EDITOR
ASSOCIATE EDITOR

DR. ABHIJIT SENGUPTA

MS. JEENATARA BEGUM
MR. DIPANJAN MANDAL

HISTORICAL ARTICLE

Ancient history of Indian pharmacy

The study of the ancient history of Indian medicine has recently

been revived due to the publication of polyglot translations.
However, little is known of ancient Indian pharmacy.
Archaeological evidence suggests the Indus people lived a settled
life approximately in 2500 B.C. Their cities were enjoying the
cleanest and most hygienic daily life with elaborate civic sanitation
systems. The whole conception shows a remarkable concern for
health. Then, the early Aryans invaded India about 1500 B.C. and
the Vedic age started. The Rgveda texts contain the hymns for
Soma and those for herbs. The term Ayurveda (i.e., science of life)
is found in some old versions of both Ramayana and Mahabharata
and in the Atharvaveda. Susruta had the credit of making a
breakthrough in the field of surgery. The Ayurveda, a work on
internal medicine, gives the following transmission of sages:
Brahma-->Daksa-->Prajapati-->Asivinau-->Indra-->Caraka. On the
other hand, the Susruta-samhita, which deals mainly with surgical
medicine, explains it as follows; Indra-->Dhanvantari-->Susruta
Both Caraka and Susruta were medical doctors as well as
pharmacists, so they studied more than 1000 herbs thoroughly.
The Ayurveda had been used by his devotees for medical purposes.
It eventually spread over Asia with the advanced evolution of
Buddhism.

Click here to go at the top

2

25-09-2015

NEWS UPDATE

World Pharmacists Day 25th September:

All over the world, on Friday 25 September, pharmacists will

celebrate World Pharmacists Day. This special day, now in its fifth
year, was established by the International Pharmaceutical
Federation (FIP), the global federation of national associations of
pharmacists and pharmaceutical scientists, which is in official
relations with the World Health Organization. Through FIPs 132
member organisations, FIP represents over three million experts in
medicines. September 25 was suggested by their Turkish members
because it is the date that FIP came into existence in 1912. The
purpose of World Pharmacists Day is to encourage activities that
promote and advocate for the role of the pharmacist in improving
health in every corner of the world. This years theme, developed
by FIP, is Pharmacist(s): your partner(s) in health.

'Remote control' of immune cells opens door to

safer, more precise cancer therapies: (24th
September, 2015)
A molecular "on switch" that allows tight control over the actions
of T cells, immune system cells that have shown great potential as
therapies for cancer, has been developed by a group of researchers.

Researchers
quantify
relationship
scientific discoveries, advances in
(24th September, 2015)

between
medicine:

Scientists have provided a detailed map of how basic research

translates into new treatments for deadly diseases. Charting the
network of discoveries that led to the development of important
therapeutic drugs, the investigators revealed that, up to now, the
path to a cure has required thousands of scientists and many
decades.

Click here to go at the top

3

25-09-2015

Newly identified mechanism solves enduring

mystery of key element of cellular organization:
(24th September, 2015)
Scientists have identified a mechanism that plays a key role in
cellular organization and function and also offers a possible new
treatment strategy for ALS and other degenerative disorders.

New methodology tracks changes in DNA

methylation in real time at single-cell resolution:
(24th September, 2015)

A tool that allows scientists to monitor changes in DNA

methylation over time in individual cells has been developed by a
group of researchers. Certain diseases, including cancer, cause
changes in DNA methylation patterns, and the ability to document
these alterations could aid in the development of novel therapies.

Newly identified biochemical pathway could be

target for insulin control: (24th September,
2015)

Researchers are reporting the identification of a new biochemical

pathway to control insulin secretion from islet beta cells in the
pancreas, establishing a potential target for insulin control.

Leukemia tumor suppressor

September, 2015)

identified:

(24th

A protein-coding gene called hnRNP K has been identified as a

tumor suppressor for acute myeloid leukemia (AML), a finding
that could be important for investigating how best to target
treatment of a blood cancer striking mostly older individuals.

New study reveals neural mechanism responsible

for fat breakdown: (24th September, 2015)

A breakthrough study shows that fat tissue is innervated and that

direct stimulation of neurons in fat is sufficient to induce fat
Click here to go at the top
4

25-09-2015

breakdown. These results set up the stage for developing novel

anti-obesity therapies.

Nanoparticles could boost effectiveness and

reduce side effects of allergy shots: (23rd
September, 2015)

Whether triggered by cats, bees, pollen or mites, allergies are on

the rise. And the bad news doesn't stop there. The only current
therapy that treats their causes is allergen-specific immunotherapy
-- or allergy shots -- which can cause severe side effects. Now,
researchers report the development of a potentially better allergy
shot that uses nanocarriers to address these unwanted issues.

Chemists design rapid, simple, inexpensive tests

using DNA: (23rd September, 2015)
Chemists have used DNA molecules to developed rapid,
inexpensive medical diagnostic tests that take only a few minutes
to perform. Their findings may aid efforts to build point-of-care
devices for quick medical diagnosis of various diseases ranging
from cancer to allergies, autoimmune diseases, sexually
transmitted diseases (STDs), and many others. The new
technology may also drastically impact global health, due to its low
cost and easiness of use, according to the research team. The rapid
and easy-to-use diagnostic tests are made of DNA and use one of
the simplest force in chemistry, steric effects a repulsion force
that arises when atoms are brought too close together to detect a
wide array of protein markers that are linked to various diseases.

Neural dysfunction in cognitive control circuits

during adolescence could be predictor of
psychotic disorders: (22nd September, 2015)
Researchers have shown that lower levels of conflict-related brain
activity are associated with a higher risk for later psychosis. Their
study offers evidence that conflict-related brain activation
Click here to go at the top
5

25-09-2015

represents an adaptive process that is diminished in individuals at

high risk for psychosis, although further study is needed, they say.
For detail mail to editor

KNOWLEDGE BASED ARTICLE

Safety of Nanomaterials in Cosmetic Products

Nanomaterials are used in a variety of FDA-regulated products

because of their unique properties, imparting potential advantages
to products considered for development. Such materials, due to
their nanoscale size, can have chemical, physical, and biological
properties that differ from those of their larger counterparts. Such
differences may include altered magnetic properties, altered
electrical or optical activity, increased structural integrity, or
altered chemical or biological activity. These new or altered
properties may affect the performance, quality, safety, and/or
effectiveness, if applicable, of a product that incorporates that
nanomaterial.
The application of nanotechnology may result in product
attributes that differ from those of conventionally-manufactured
products, and thus may merit particular examination.
A. General Framework for Assessing the Safety of
Nanomaterials in Cosmetic Products
Section 301(a) of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 331(a)) prohibits the marketing of
adulterated or misbranded cosmetics2 in interstate commerce. The
FD&C Act does not subject cosmetics or cosmetic ingredients
(with the exception of color additives) to FDA premarket approval
in order to be marketed legally in the United States. Except for
color additives and those ingredients that are prohibited or
restricted from use in cosmetics by regulation, a manufacturer may
use any ingredient in the formulation of a cosmetic provided that
the use of the ingredient does not otherwise cause the cosmetic to
Click here to go at the top
6

25-09-2015

be adulterated (section 601 of the FD&C Act (21 U.S.C. 361)) or

misbranded (section 602 of the FD&C Act (21 U.S.C. 362)).
Cosmetic product manufacturers must ensure that the product is
not misbranded or adulterated. The FD&C Act does not give us
the authority to require that safety data be submitted to us or to
approve a cosmetic product before it is marketed. Nevertheless,
manufacturers or distributors are responsible for obtaining all data
and information needed to substantiate the safety of their products
before introducing them into the marketplace.
In the Federal Register of March 3, 1975 (40 FR 8912 at 8916), we
advised that the safety of a product can be adequately
substantiated through (a) reliance on already available
toxicological test data on individual ingredients and on product
formulations that are similar in composition to the particular
cosmetic, and (b) performance of any additional toxicological and
other tests that are appropriate in light of such existing data and
information. Although satisfactory toxicological data may exist for
each ingredient of a cosmetic product, it will still be necessary to
conduct some toxicological testing with the complete formulation
to assure adequately the safety of the finished cosmetic.
These general principles are applicable to the safety substantiation
of cosmetic products whether they contain nanomaterials or
conventionally manufactured ingredients. In applying these
principles, however, it may be important to give particular
consideration to the fact that a material at nanoscale may show
changes in, or have novel, physicochemical properties, behaviors,
and/or effects that could be different from a larger scale material
with the same chemical composition.
For example, the small particle size of a nanomaterial has the
potential to alter the distribution and bioavailability of that
material compared to a larger scale material with the same
chemical composition. The small size leads to increased surface
area relative to the mass of the particle, which could result in
increased biological interactions. In addition, the uptake,
Click here to go at the top
7

25-09-2015

absorption, and biodistribution of the material may be altered,

leading to potential systemic exposure.
In some cases, the traditional testing methods that have been used
to determine the safety of cosmetic ingredients and finished
products may not be fully applicable due to a nanomaterials
distinctive properties and behavior. Such distinctive
physicochemical characteristics or biological interactions may
affect the results or interpretation of results obtained from
traditional toxicology testing, which form an integral part of safety
substantiation.
B. Points to Consider in Assessing the Safety of Nanomaterials
in CosmeticProducts
Just as the traditional safety assessment includes material
characterization and toxicology considerations, safety evaluations
of cosmetic products containing nanomaterials should also take
these considerations into account. Nanomaterials may exhibit new
or altered physicochemical properties that may affect biological
interactions, which may raise questions about the safety of the
product containing nanomaterials. Any such unique properties or
biological effects of nanomaterials should be identified and
appropriately addressed during safety evaluations.
With respect to nanomaterial characterization, safety should be
assessed through fully describing the nanomaterial and evaluating
a wide range of physical and chemical properties, as well as
through the assessment of impurities, if present. The toxicology
and absorption, distribution, metabolism, and excretion
considerations for nanomaterials in cosmetic products can be
informed by addressing the routes of exposure, the uptake and
absorption, and toxicity testing. In addition, any distinctive
properties and biological behavior of nanomaterials should be
considered in determining the suitability of traditional testing
methods for toxicity testing of cosmetic products containing
nanomaterials. As needed, traditional toxicity testing methods
should be modified or new methods developed to address: (1) the
key chemical and physical properties that may affect the toxicity
Click here to go at the top
8

25-09-2015

profile of nanomaterials and (2) the effects of those properties on

the function of the cosmetic formulation. The toxicological testing
should include consideration of toxicity of both the ingredients
and impurities; dosimetry for in vitro and in vivo toxicology studies, if
needed; clinical testing, if warranted; and toxicokinetics and
toxicodynamics. The overall package of data and information
should substantiate the safety of the product under the intended
conditions of use.
1. Nanomaterial Characterization
Nanomaterials vary widely in composition, morphology, and other
characteristics and cannot be considered a uniform group of
substances. These substances may have physical, chemical, or
biological properties that are different from those of larger scale
material with the same chemical composition. As stated earlier,
such differences may include altered magnetic properties, altered
electrical or optical activity, increased structural integrity, or
altered chemical or biological activity.
As discussed in the FDA Task Force report, studies indicate that
various attributes of a particular nanoscale material, including
increased surface-area-to-volume ratio, morphology, surface
features, and charge, can affect the distribution of that material in
the body and that materials interaction with biological
systems. Therefore, thorough characterization of nanomaterials
can form an integral part of the safety assessment. This would
include proper identification of the chemical composition as well
as impurities, structure, and configuration of the nanomaterial(s)
used in the cosmetic product. In addition, characterization of the
nanomaterial(s) as present in the raw material, formulation, test
media, and in the relevant biological environment for toxicological
testing should be considered to help determine potential biological
interactions and effects. In addition, stability of the nanomaterial
under testing conditions and in a formulation under intended
conditions of use should be determined.

Click here to go at the top

9

25-09-2015

o
o

o
o
o
o

o
o
o
o

a. Physicochemical Properties
As with any cosmetic ingredient, the nanomaterial should be fully
described, including:
the nanomaterial name,
the Chemical Abstracts Service (CAS) number,
the structural formula,
the elemental and molecular composition including:
the degree of purity, and
any known impurities or additives.
A thorough understanding of the details of the manufacturing
process will help identify residual additives and impurities, as well
as certain other physical and chemical properties.
A wide range of physical and chemical properties should be
evaluated to help determine if a substance produced with
nanotechnology is safe for the proposed use. Proper
characterization should include, as appropriate:
measurement of particle size and distribution,
aggregation and agglomeration characteristics,
surface chemistry, including:
zeta potential/surface charge,
surface coating,
functionalization, and
catalytic activity
morphology including:
shape,
surface area,
surface topology, and
crystallinity
solubility,
density,
stability, and
porosity.
Although a wide range of analytical techniques are available for
measurement of physicochemical properties of materials, many of
these methods have not been validated for the evaluation of
Click here to go at the top
10

25-09-2015

nanomaterials in cosmetic products. Therefore, appropriate

analytical methods suitable for the specific nanomaterial and the
cosmetic product formulation should be chosen, and results
obtained from such tests appropriately interpreted and reported
for adequate characterization of the material.
b. Impurities
As with any cosmetic ingredient, a change in the starting material
used to prepare a formulation will likely result in altered
composition of the final product, which may result in different
impurities. Variables such as altered purity or changes in the
starting material should be considered. A manufacturer should
assess the identity and quantity of impurities and how they may
affect the overall safety of the end product.
It is also important to understand how the nanomaterial is
manufactured. Nanoscale impurities may arise from the
manufacturing process. Changes in the manufacturing process,
including use of different solvents, time/temperature conditions
and changes to the starting chemicals (e.g., alternative starting
materials, different purity levels or different concentrations of the
chemicals used in the process) may change the types and/or
quantities of impurities in the final product. Additional agents,
such as dispersing agents and surface modifiers, are often used in
the manufacture of nanomaterials. These additional agents and
impurities should be considered in the safety substantiation for
nanomaterials in cosmetic products.
2. Toxicology Considerations
The appropriateness of toxicological testing depends on the
intended use, exposure levels, and degree of concern for potential
toxicity of an ingredient or formulation. In determining what
toxicological testing may be appropriate, manufacturers should
consider each ingredients chemical structure and composition,
and physicochemical properties, purity/impurities, agglomeration
and size distribution, stability, conditions of exposure, uptake and
absorption, bioavailability, toxicity, and any other qualities that
may affect the safety of the product for its intended
Click here to go at the top
11

25-09-2015

use. Manufacturers should address both short-term and long-term

toxicity of nanomaterials, and consider the need to evaluate the
possibility of ingredient-ingredient interactions or ingredientpackaging interactions.
Where traditional toxicity test methods are used, manufacturers
should consider the applicability of the test methods and, as
needed, modify them with respect to such factors as appropriate
solvents and dosing formulations, solubility, agglomeration and
aggregation of particles, and stability conditions associated with
the cosmetic product containing nanomaterials. For example,
whether a nanomaterial is soluble, insoluble, or partially-soluble
may affect the suitability of a traditional toxicity test
method. Some traditional in vivo test methods may be suitable for
only soluble nanomaterials. Some traditional in vitro and in vivotest
methods may need to be adjusted for testing insoluble or partiallysoluble nanomaterials. These considerations are important
because nanoparticles tend to stick to each other to form larger
agglomerates/aggregates that may be insoluble. Therefore, in a
dosing or test medium, nanomaterials may be present as a nanodispersion rather than in solution. Agglomeration and aggregation
of particles is another factor that may affect the suitability of
traditional toxicity testing methods, and manufacturers should
ensure that testing appropriately reflects the range of free particles
and any aggregates or aggolomerates found in the cosmetic
product formulation. Toxicological testing may need to be
conducted separately on the free nanoparticles and the
agglomerated/aggregated nanoparticles because they will likely
have different chemical and biological properties. Due to their high
surface energy, nanomaterials may also interact with the testing
medium or bind to different substances, including proteins, in the
test medium, resulting in an altered biological activity. Thus,
manufacturers should consider and make necessary adjustments to
traditional toxicity testing methods, taking into account the
specific characteristics of the nanomaterial as it is intended to be
used in the cosmetic product. In instances where traditional
Click here to go at the top
12

25-09-2015

toxicity testing methods cannot be satisfactorily modified, FDA

recommends developing new methods to adequately assess the
toxicity of the nanomaterial in the cosmetic product and ensure
the product is safe.
It is also important to mention that the dose metrics currently
used for toxicological testing of conventionally manufactured
chemicals (measured and expressed in mass, volume or number of
particles such as mg/kg, or mg/L) may not be appropriate for
nanomaterials because of their large surface area per particle mass
or volume. In addition to weight/volume metrics, evaluations of
the safety of nanomaterials should also consider alternative
metrics, such as weight/volume concentration, particle number
concentration and surface area, until suitable parameters for dose
metrics become available.
a. Routes of Exposure
The safety of an ingredient is based in part on the potential for
exposure and the relevant routes of exposure that are determined
by its intended use and its application. Although most cosmetic
products are applied directly to the skin, some products may be
applied by spray presenting the possibility of inhalation
exposure. Additionally, some cosmetic products are applied in an
area where there is the possibility of oral exposure. Additionally,
systemic absorption can result from dermal, inhalation, ocular and
oral exposures. Therefore, for nanomaterials, the dose to the
primary exposure organs as well as the dose to any secondary
target organs should be considered in developing or modifying
toxicological testing methods and for evaluating the test data.
b. Uptake and Absorption
As stated above, some nanomaterials have unique physicochemical
properties that may alter the potential toxicity of a compound (e.g.
reduction in particle size could increase the ability for the
compound to be absorbed). Therefore, the safety assessment
should address whether there will be an increase in uptake,
absorption, transport into cells, and transport across barriers (e.g.
blood-brain barrier) or altered bioavailability or biological half-life.
Click here to go at the top
13

25-09-2015

For example, there may be an increase in the dose delivered to

sensitive tissues due to the increased ability of the nanomaterial to
pass through the blood-brain barrier.
Nanomaterials used in cosmetic products can be divided into two
groups: (1) soluble and/or biodegradable nanoparticles, which
disintegrate into their molecular components (e.g. some liposomes
and nanoemulsions) upon application to skin and thus may not
raise safety questions, and (2) insoluble, sufficiently stable and/or
biopersistent nanoparticles (e.g. titanium dioxide (TiO2),
fullerenes, and quantum dots). Some insoluble, partially-soluble or
sufficiently stable nanomaterials, particularly those in the lower
nanoscale range and with certain surface characteristics, may be
able to cross biological membrane barriers (Ref. 25) and may have
harmful effects due to the potential interaction with organs and
cellular compartments. Thus, when there is evidence of systemic
exposure to nanomaterials, manufacturers should consider
including absorption, distribution, metabolism, and excretion
(ADME) parameters in safety assessments of the nanomaterial in
the cosmetic product.
For exposure via dermal absorption, studies should be conducted
with both intact skin and impaired skin (e.g. sunburned, atopic,
eczematous, psoriatic, or systematically damaged skin) to address
the possibility of an increased rate of penetration and ability of the
ingredient to become systemically absorbed. The passive transport
of many nanomaterials may not occur through intact skin, but
there is an increased probability for entry of nanomaterials
through skin with an impaired barrier layer.
The use of aerosolized cosmetic products can also result in
exposure to nanomaterials via the respiratory tract. The
deposition of nanomaterials in the respiratory system depends on
their aerosol properties and interactions with respiratory
epithelium. The soluble nanoparticles may be dissolved,
metabolized and transported to other organs and blood whereas
the insoluble nanoparticles may be either retained in the airways
and result in pulmonary effects or swallowed by coughing and
Click here to go at the top
14

25-09-2015

cleared. The physical characteristics, including surface

properties of nanomaterials, are important factors that
warrant careful attention, particularly for inhaled nanoscale
particles. Studies have indicated that decreasing the size of
particles and increasing the surface area can result in potential
adverse effects not only in the respiratory system, but also in the
heart and blood vessels, the central nervous system, and the
immune system.
Exposure via the oral route is generally limited to those products
that are introduced into or applied near the mouth (e.g.,
mouthwash, lipsticks). Limited evidence suggests that the uptake
of nanomaterials and systemic absorption depends on their size,
surface charge, and surface ligand modification. Additional studies
have indicated that nanomaterials have limited uptake in the
gastrointestinal tract, but the translocation to certain regions of
the intestinal barrier can be substantially increased.
Therefore, we recommend that the safety assessment process for
nanomaterials include the issues of toxicokinetics and
toxicodynamics with reference to different exposure routes.
c. Toxicity Testing
The initial step in the evaluation of the safety assessment of
cosmetic products is to conduct toxicity testing based on a
toxicological profile of the ingredients and their routes of
exposure. There are several guidelines for conducting toxicity
testing (tiered testing strategy) of chemicals that can be used as a
starting point in evaluating toxicity of nanomaterial ingredients.
Consistent with the guidelines issued by the Cosmetic, Toiletry
and Fragrance Association (CTFA) and the Organization for
Economic Co-operation and Development (OECD), at a
minimum, testing for acute toxicity, skin irritation, ocular
irritation, dermal photoirritation, skin sensitization, mutagenicity/
genotoxicity, repeated dose (21-28 days) toxicity, and subchronic
(90 days) toxicity. Phototoxicity testing for a cosmetic product
that is intended to be used on sun-exposed skin. Results obtained
from this basic test battery may indicate a need for additional
Click here to go at the top
15

25-09-2015

testing. Where available, other relevant data, such as toxicological

data on individual ingredients that are similar in composition to
the nanomaterial or data on a larger scale material with the same
chemical composition as the nanomaterial, can also be considered.
As stated previously, in designing tests for use with nanomaterials
in cosmetics products, manufacturers should consider modifying
traditional toxicity testing with respect to such factors as
appropriate solvents and dosing formulations, agglomeration of
particles, purity and stability conditions, and other variables. New
methods may also need to be developed if traditional tests cannot
be modified satisfactorily. For example, the Ames test,
recommended as part of a battery of genotoxicity testing for
conventional chemicals, may not be suitable for insoluble or
partially-soluble nanomaterials used in cosmetic products because
the bacterial cell wall may create a possible barrier for many
nanomaterials.
Toxicity testing in vivo has long been considered indispensable for
obtaining information on translocation, biodistribution,
accumulation, and clearance. As mentioned earlier, while
conducting in vivo toxicity testing for nanomaterials, careful
attention should be paid to the issue of dose metrics (mass, volume
or number of particles). The manufacturer should consider the
surface area and number of particles, as well as mass concentration
in the study design of in vivo toxicity testing. For in vivo studies via
the dermal route of administration, the test substance should be
applied directly to the skin, and for the oral route of
administration, the test substance should be given either by gavage
or in the diet. Agglomeration or aggregation characteristics of
nanomaterials in the topical vehicle, gavage or feed matrix are
other important factors to assess prior to conducting these studies
for safety assessment. Additionally, the potential for nanomaterials
to penetrate through the skin or be absorbed through the gut and
becoming available for biodistribution, should be addressed while
Click here to go at the top
16

25-09-2015

1.
2.
3.
4.
5.

estimating the risks associated with the exposure to

nanomaterials.
There has been recent emphasis on the development of validated
methods for in vitro testing of cosmetic products by the Interagency
Coordinating Committee on the Validation of Alternative Methods
(ICCVAM) and the European Center for the Validation of
Alternative Methods (ECVAM). The seventh amendment to
Directive 2003/15/EC of the European Parliament and of the
Council instituted a ban on animal testing of cosmetic products in
2004 and a ban on certain animal tests with validated alternatives
in March 2009. We recommend validation of in vitro methods for
safety testing of cosmetic products and ingredients and optimizing
these models for nanomaterials, with particular attention being
paid to the issues of cytotoxicity and precipitation of insoluble
ingredients. Nanomaterials can settle, diffuse, and aggregate
differentially according to their size, density, and surface
chemistry. Thus, the assessment of the agglomeration or
aggregation of nanomaterials in the media used in the in
vitro system should be addressed.
Alternative testing methods currently under consideration that
can be optimized for a specific nanomaterial and might be useful to
help determine ingredient safety include:
Reconstructed human skin such as EpiskinTM and Epiderm TM
for skin irritation and corrosion testing;
Phototoxicity testing via 3T3 NRPT (3T3 fibroblasts neutral red
uptake phototoxicity testing) applicable to ultra violet (UV)
absorbing substances;
Human/pig skin in a diffusion cell for dermal absorption;
Bovine Corneal Opacity and Permeability (BCOP) and the Isolated
Chicken Eye (ICE) for ocular irritation; and
Genotoxicity testing using a battery of recommended tests
covering the endpoints of gene mutation, and structural and
numerical aberrations. While conducting genotoxicty tests, the
nanomaterials specific properties should be taken into account to
understand the mechanism of nanomaterials genotoxic effects .
Click here to go at the top
17

25-09-2015

In vivo studies may be more suitable for nanomaterials with

limited solubility properties.
Jeenatara Begum
Assistant Professor
GNIPST

DISEASE RELATED BREAKING NEWS

Middle East respiratory syndrome coronavirus

(MERS-CoV) Kuwait: (23rd September, 2015)

On 19 September 2015, the National IHR Focal Point of Kuwait

notified WHO of 1 additional fatal case of Middle East respiratory
syndrome coronavirus (MERS-CoV) infection.
Read more

UPCOMING EVENTS

3rd International Conference and Exhibition on Pharmacognosy,

Phytochemistry & Natural Products will be held on 26th to 28th
October, 2015 at Hydrabad.

DRUGS UPDATES

FDA Approves Lonsurf (tipiracil and trifluridine)

for
Advanced
Colorectal
Cancer:
(22nd
September, 2015)
The U.S. Food and Drug Administration approved Lonsurf (a pill
that combines two drugs, trifluridine and tipiracil) for patients
with an advanced form of colorectal cancer who are no longer
responding to other therapies.

Read more

Click here to go at the top

18

25-09-2015

CAMPUS NEWS
INDOOR BATTLE 2015

On 24th September, 2015 GNIPST organised the Indoor games

(Table Tennis, Carrom, Chess for both Boys and Girls) Indoor
Battle 2015.
Congratulations to all winners and participants.
The Winners are:

Table Tennis (for Boys):

1st: Soumen Dhara (M.Pharm, 2nd year [Pharmacology])
2nd: Ratul Banduri (B.Pharm, 3rd year)
3rd: Sneham Sen (B.Pharm, 3rd year)
Table Tennis (for Girls):
1st: Sweta Saha (B.Sc [BT], 3rd year)
2nd: Moutan Roy (B.Pharm, 2nd year)
Carrom (for Boys):
1st: Sk. Sajjat Ali (B.Pharm, 4th year) and Sk. Abdul Aslam
(B.Pharm, 3rd year)
2nd: Sourabh Saha (B.Pharm, 4th year) and Rajib Singha Roy
(B.Pharm, 4th year)
3rd: Arnab Banerjee (M.Pharm, 2nd year [Pharmaceutics])
and Achinta Banerjee (M.Pharm, 2nd year [Pharmaceutics])
Carrom (for Girls):
1st: Sreyashee Mitra (B.Pharm 4th year) and Rituparna Das
(B.Pharm 4th year)
2nd: Rinita DasBhowmik (B.H.M, 1st year) and Tania Datta (B.H.M,
1st year)
3rd: Sushmita Sen (D.Pharm, 2nd year) and Keya Das (D.Pharm, 2nd
year)
Chess (for Boys):
1st: Sayantan Dutta (B.Pharm, 3rd year)
2nd: Tanmoy Das Biswas (B.Pharm 4th year)
Click here to go at the top
19

25-09-2015

Chess (for Girls):

1st: Rituparna Das (B.Pharm 4th year)
2nd: Suchetana Dutta (B.Pharm 4th year)
3rd: Krishnakali Basu (B.Pharm 4th year)
SAGAR DUTTA MEDICAL COLLEGE FEST-ASTERICA 2015
WINNER:
The students of GNIPST stood first in the FASHION SHOW
competition of Sagar Dutta Medical College Fest:
Congratulation to the participantsSouvik Ganguly (B.H.M 2nd year)
Riya Taran (B.Pharm 4th year)
Moktar Hossain (B.Pharm 4th year)
Chandrika Saha (B.Pharm 4th year)
Swaranjeet Banik (B.Pharm 4th year)
Sampita Pal (B.Pharm 3rd year)
Ranit Kundu (M.Pharm 1st year)
Susmita Kar (B.Pharm 2nd year)
Md. Nadeem Shah (B.Pharm 4th year)
Sreyashee Mitra (B.Pharm 4th year)
Sunanda (M.Pharm 1st year)
Best Male Model of ASTERICA 2k15:
Souvik Ganguly (B.H.M 2nd year)
Best Female Model of ASTERICA 2k15:
Sampita Pal (B.Pharm 3rd year)
Anchor:
Sreejita Roy (B.Sc )
Solo Singing competition:
Sayantan Goswami (B.Pharm 4th year):winner
Arpita (B.Sc) :2nd runner up
CARNIVAL OF CANVASS:
On 4th September the Students of GNIPST celebrated the freshers
party for Masters degree students.
On 4th September the students of GNIPST celebrated Teachers
Day.
Click here to go at the top
20

25-09-2015

ESPERANZA:

On 21st August, 2015 the 1st year students of GNIPST were

welcomed in the Freshers Welcome Programme ESPERANZA.
HOMAGE TO FORMER PRESIDENT DR A P J ABDUL
KALAM:
On 31st July, 2015 all the students and teachers of GNIPST paid
their homage for our former president Dr. A P J Abdul Kalam.
ALUMNI ASSOCIATION:
GNIPST has been certified by the Alumni Association under the
West Bengal Societies Registration Act, 1961.
FAREWELL PROGRAMME:
On 15th May 2015 GNIPST celebrated the farewell programme
Sesh Chithi for the final year students of M.Pharm, M.Sc,
B.Pharm, B.Sc and BHM.
JIS SAMMAN 2015
On 11th May, 2015 GNIPST attended the JIS SAMMAN 2015.
JIS SAMMAN Awards:
Best College (Non Engineering):
GNIPST
Best Principal:
Dr (Prof.) Avijit Sengupta
Best HOD:
Mr. Jaydip Ray
Best Faculty:
Mr. Debabrata Ghoshdastidar (Pharmacy)
Dr. Swati Chakraborty (Life Sciences)
Best faculty since inception:
Mr. Jaydip Ray
Best Office Staff:
Ms. Jaya Banerjee
Best technical Assistant:
Mr. Somnath Majhi

Click here to go at the top

21

25-09-2015

College Blue:
Avik Paul
Highest DGPA of 2014:
B.Pharm:
Purbali Chakraborty (4th year)
Diksha Kumari (3rd year)
Aishika Dutta (2nd year)
Sampita Paul (1st year)
M.Pharm:
Aritra Mukherjee (Pharmaceutical Chemistry)
Mounomukhar Bhattacharya (Pharmacology)
B.Sc (Biotechnology):
Papiya Saha (3rd year)
Shomasree Das (2nd year)
Ayanita Basak (1st year)
B.Sc (Microbiology):
Bonhisikha Chatterjee (3rd year)
Riaz Hossain (2nd year)
Soumi Chowdhury (1st year)
BHM:
Bishal Roy (3rd year)
Shreyabhanja Chowdhury (2nd year)
Recitation:
Udita Majumder
Debate:
Srijita Roy
Poushali Ganguly
Quiz:
Arani
Dipayan Nath
Band:
Syantan Ghoswami
Anurag Ghosh
Atanu Mondal

Ray

Click here to go at the top

22

25-09-2015

Arka Khamaru
Ritobroto Paul
Abhirup Dasgupta
Fashion:
Md. Nadeem Shah
Koustav Sarkar
Shaksar Saha
Avirup Dasgupta
Ranit Kundu
Namrata Ganguly
Shreyasee Mitra
Chandrika Saha
Debopriya Chatterjee
Riya Taran
Innovative Modeling:
Ankit Chowdhury
Kartik Koley
Mudasar Manna
Dipan Chaterjee
Abhishek Singh
Kaustav Pal
Manojit Dutta
SPIRIT JIS 2015
On 03th to 05th April, 2015 JIS organised SPIRIT JIS 2015.
GPAT 2015 Result:
The following B.Pharm. final year students have qualified, GPAT2015. We congratulate them all.
Diksha Kumari
Rupanjay Bhattacharya
Avik Paul
Xtasy 2015:
GNIPST is going to organize the Tech Fest Xtasy 2015 from 30th
March, 2015 to 1st April, 2015.

Click here to go at the top

23

25-09-2015

FINISHING SCHOOL TRAINING PROGRAMME:

The FINISHING SCHOOL TRAINING PROGRAMME was

organized by the Entrepreneurship Development Cell and Training
& Placement Cell, GNIPST in collaboration with Indian Pharmacy
Graduates Association (IPGA), Bengal Branch from 21st February
to 11th April, 2015 at GNIPST Auditorium.
st
On 21 February, 2015 the Finishing School Training Programme of
GNIPST was inaugurated by Sri Soumen Mukhopadhyay, Deputy
Director, Drug Control Office, Goutam Kr. Sen, President, IPGA,
Mr. Subroto Saha, Asst. Directorate, Drug Control Office, Mr.
Ranendra Chakraborty, Sales Manager and Associate Director Dr.
Reddys Laboratory.
On 28th February, 2015 Dr. D. Roy, Former Deputy Drug
Controller, Mr. Sujoy Chakraborty, divisional Therapy Manager,
Cipla and Mr. Vikranjit Biswas, Senior Manager, Learning &
Development, Cipla delivered their valuable lectures in the 2nd day
FINISHING SCHOOL TRAINING PROGRAMME of GNIPST.
On 14th March, 2015 Mr. Milindra Bhattacharya, Senior Manager,
QA & QC, Emami Ltd. and Mr. Joydev Bhoumik, Manager,
Operation, Ranbaxy Laboratory Limited delivered their valuable
lectures in the 3rd day FINISHING SCHOOL TRAINING
PROGRAMME of GNIPST.
On 21st March, 2015 Mr. Tridib Neogi, Associate Vice-President
(Quality Assurance), Albert David Ltd. delivered his valuable
lectures in the 4th FINISHING SCHOOL TRAINING
PROGRAMME of GNIPST.
On 28th March, 2015 Dr. Gautam Chaterjee, an Alumni of Jadavpur
University and presently associated with NIPER delivered his
valuable lectures in the 5th FINISHING SCHOOL TRAINING
PROGRAMME of GNIPST.
On 11th April, 2015 the closing ceremony of the FINISHING
SCHOOL TRAINING PROGRAMME was held in GNIPST
Auditorium.
Click here to go at the top
24

25-09-2015

JOBS:

All the students of Final Year B. Pharm and M. Pharm are hereby
informed that an interview will be conducted on 23rd May, 2015 by
Standard Pharmaceuticals Ltd. GSK for post: Production, QA, QC.
All the students of Final Year B. Pharm and M. Pharm are hereby
informed that an interview will be conducted by GSK for sales and
marketing job.
Details given below:
Date: 27.03.2015
Time: 09:45 am
Venue : GSK Consumer Healthcare Limited, Unit No. 208,
nd
2 Floor, Ecospace Campus B (3 B), New Town,
Rajarhat, 24 Pgs (N). Kolkata-700156.
THYROCARE provisionally selected 15 students from JIS Group.
Amongst these, 3 students of B. Sc (H) Biotechnology and M. Sc
Biotechnology have been selected.
Ipsita Mondal (M. Sc Biotechnology)
Debriti Paul (M. Sc Biotechnology)
Debopriya Chatterjee {B. Sc (H) Biotechnology}
The final year students of B.Pharm (31 students) and B.Sc (11
students) attended the pooled campus drive of Abbott India Ltd.
on 10th March, 2015 at Jadavpur University. Among them 17
students have gone through to the final round of this pooled
campus drive and short listed for final selection.
ACHIEVEMENT:
Congratulations to Anurag Chanda, student of B.Pharm final year
who have got the 1st prize in poster presentation event in Prakriti
2015 at Department of Agricultural and Food engineering, IIT,
Kharagpur.
OTHERS:
On 24th and 25th February, 2015 Swamiji of Gourio Math was
delivered some motivational lectuers in GNIPST.
Click here to go at the top
25

25-09-2015

The students of GNIPST participated in the 4 Sardar Jodh

th

th

SinghTrophy organised by NIT on 20 February, 2015.

On 8th February, 2015 Gnipst celebrated the Reunion
programmeReminiscence Reloaded 2015.

STUDENTS SECTION
WHO CAN ANS WER FIRS T????

"Strength's Origin is in Science" is the

motto of which Indian organization?
Answer of Previous Issues Questions:
Fear of Injection

Identify the person

Answer of Previous Issues Image:

J manjula, dedo head

Send

your
thoughts/
Quiz/Puzzles/games/write-ups or any other
contributions for Students Section& answers
of this Section at gnipstbulletin@gmail.com

Click here to go at the top

26

25-09-2015

EDITORS NOTE
It is a great pleasure for me to publish the 2nd issue of 49th Volume
of GNIPST BULLETIN. All the followers of GNIPST BULLETIN
are able to avail the bulletin through facebook account GNIPST
bulletin I am very much thankful to all the GNIPST members and
readers who are giving their valuable comments, encouragements
and supports. I am also thankful to Dr. Abhijit Sengupta, Director
of GNIPST for his valuable advice and encouragement. Special
thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar
and Mr. Soumya Bhattacharya for their kind co-operation and
technical supports. Thank you Mr. Soumya Bhattacharya for the
questionnaires of the student section. An important part of the
improvement of the bulletin is the contribution of the readers. You
are invited to send in your write ups, notes, critiques or any kind of
contribution for the forthcoming special and regular issue.
ARCHIVE
The general body meeting of APTI, Bengal Branch has been
conducted at GNIPST on 15th June, 2012. The program started with
a nice presentation by Dr. Pulok Kr. Mukherjee, School of Natural
Products, JU on the skill to write a good manuscript for
publication in impact journals. It was followed by nearly two hour
long discussion among more than thirty participants on different
aspects of pharmacy education. Five nonmember participants
applied for membership on that very day.
GNIPST is now approved by AICTE and affiliated to WBUT for
conducting the two years post graduate course (M.Pharm)
in PHARMACOLOGY. The approved number of seat is 18.
The number of seats in B.Pharm. has been increased from 60 to
120.
Click here to go at the top
27

25-09-2015

AICTE has sanctioned a release of grant under Research

Promotion Scheme (RPS) during the financial year 2012-13to
GNIPST as per the details below:
a. Beneficiary Institution: Guru Nanak Institution of Pharmaceutical
Science & Technology.
b. Principal Investigator: Dr. LopamudraDutta.
c. Grant-in-aid sanctioned:Rs. 16,25000/- only
d. Approved duration: 3 years
e. Title of the project: Screening and identification of potential
medicinal plant of Purulia & Bankura districts of West Bengal
with respect to diseases such as diabetes, rheumatism, Jaundice,
hypertension and developing biotechnological tools for enhancing
bioactive molecules in these plants.

Activity Clubs of GNIPST:

Name of Club
SPORTS
LITERARY AND PAINTING
SCIENCE AND INNOVATIVE
MODELLING
ECO
SOCIAL SERVICES
PHOTOGRAPHY
CULTURAL
DEBATE AND EXTEMPORE

Member Faculty
Mr. Debabrata GhoshDastidar
Ms. Jeenatara Begum
Mr. Samrat Bose
Ms. Sumana Roy
Dr. Asis Bala
Ms. Sanchari Bhattacharya
Ms. Priyanka Ray
Mr. Soumya Bhattacharya

Click here to go at the top

28